20 May 2013
Keywords: bayer/onyx, submit, snda, nexavar, hcc, german, drug
Article | 02 July 2007
German drug major Bayer and the USA's Onyx Pharmaceuticals have submitted a supplemental New Drug Application for Nexavar (sorafenib)
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 July 2007
2 July 2007
© 2013 thepharmaletter.com